First-in-human study of a new drug for advanced solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called MC002 for advanced solid tumors that have not responded to standard treatments. The purpose is to find a safe dose and see if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced solid tumors (cancer) that has spread or come back, and you have already tried standard treatments or there is no standard treatment
- You can take care of yourself (Eastern Cooperative Oncology Group performance status 0 or 1)
- You have at least one measurable tumor (as checked by scans)
- Your organ functions (like liver, kidney, heart) are adequate
- You are not pregnant or nursing, and you agree to use effective contraception if you could have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.